Akhilam Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.38 M
- Company Age 30 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.30 M
- Revenue Growth 16.12%
- Profit Growth 23.37%
- Ebitda 78.06%
- Net Worth 1.36%
- Total Assets 2.52%
About Akhilam Pharmaceuticals
Akhilam Pharmaceuticals Pvt Ltd (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 December 1994 and has a history of 30 years and two months. Its registered office is in Kannur, Kerala, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.38 M.
The company currently has active open charges totaling ₹1.30 M.
Jyothi and Dinachandran serve as directors at the Company.
Company Details
- Location
Kannur, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231KL1994PTC008470
- Company No.
008470
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Dec 1994
- Date of AGM
26 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Akhilam Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinachandran  | Managing Director | 15-Dec-1994 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jyothi | Director | 15-Dec-1994 | Current |
Financial Performance of Akhilam Pharmaceuticals.
Akhilam Pharmaceuticals Pvt Ltd, for the financial year ended 2019, experienced significant growth in revenue, with a 16.12% increase. The company also saw a substantial improvement in profitability, with a 23.37% increase in profit. The company's net worth moved up by a moderate rise of 1.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Akhilam Pharmaceuticals?
In 2017, Akhilam Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.30 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.13 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Mar 2006 | State Bank Of India | ₹0.60 M | Open |
| 14 Mar 1998 | State Bank Of India | ₹0.70 M | Open |
How Many Employees Work at Akhilam Pharmaceuticals?
Unlock and access historical data on people associated with Akhilam Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Akhilam Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Akhilam Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.